Quirk Gerald E 4
4 · Syros Pharmaceuticals, Inc. · Filed Oct 2, 2024
Insider Transaction Report
Form 4
Quirk Gerald E
Chief Legal Officer
Transactions
- Tax Payment
Common Stock
2024-09-30$2.10/sh−3,100$6,510→ 46,657 total - Exercise/Conversion
Common Stock
2024-09-30+10,000→ 49,757 total - Exercise/Conversion
Restricted Stock Units
2024-09-30−10,000→ 20,000 total→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on September 12, 2023. These restricted stock units vested as to one third (1/3rd) of the shares underlying the award on September 30, 2024, and are scheduled to vest as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.